Enzyme immunoassay for the quantitative determination of antibodies to Infliximab (Remicade®) in serum and plasma with confirmation.

This kit has been especially developed for the quantitative antibodies to infliximab in serum and plasma samples

Infliximab (Remicade) was associated to the development of anti-Infliximab antibodies, even some were reported to be neutralizing, in various percentages of patients during therapy with the drug Remicade®. This might lead to severe complications. This kit can be efficiently used for monitoring anti-Infliximab antibodies during therapy and offers the clinician a tool for decision on possible preventive measures such as possible addition of immunosuppressive drug to reduce anti-Infliximab antibodies.

All SHIKARI® ELISA kits are suitable for biosimilar work.

All SHIKARI® ELISA kits are produced under ISO 13485 quality system and have CE IVD mark.

For technical inquiry, please contact techsupport@matriksbiotek.com

Matriks Biotek® is a biotechnology company that conducts research on biotechnology, developing products and offering its products at a global scale helping people to lead a better life.